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Abstract Objective: To explore biomarkers of predicting the progression of cervical intraepithelial neoplasia grade 1 (CIN1) in women
with positive human papillomavirus (hrHPV). Methods: From October 2010 to August 2012 in Shanxi, Henan, Jiangxi province, 7,543
women underwent hrHPV DNA and E6 protein (OncoE6) screening tests. Women with either positive results were referred to colposco-
py for biopsy and followed up after one year. Women with hrHPV positivity or CIN1 were included in the analysis. Results: A total of
794 eligible women were included in the final analysis; among them, 88 women progressed histologically in one year. The relative risk
of progression for women with intermediate/high hrHPV viral load compared to low hrHPV viral load was 2.9 (95%CI: 1.8-4.8); corre-
spondingly, the figures in women with positive HPV16/18/45 and OncoE6 were 2.4 (95%CI: 1.5-3.9) and 2.9 (95%CI: 1.5-5.9), respec-
tively. The corresponding absolute risks for progression to CIN2+ were 4.9% (95%CI: 3.2-7.4), 9.0% (95%CI: 5.5-14.3), and 18.8% (95%
CI: 10.2-31.9), respectively. The absolute risk of progression for women with intermediate/high hrHPV 16/18/45 viral load and positive
OncoE6 was as high as 32.4%. Conclusions: The hrHPV intermediate/high viral load, HPV16/18/45 genotyping, and E6 protein (On-
coE6) showed promising predictive value for cervical precancer. In particular, women with intermediate/high hrHPV viral load and On-
coE6 positivity should be followed up closely.
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摘要 目的：探讨预测高危型人乳头瘤病毒（high risk human papillomavirus，hrHPV）阳性和宫颈上皮内瘤样病变1级（cervical in⁃
traepithelial neoplasia grade 1，CIN1）妇女进展的生物学标志物。方法：2010年10月至2012年8月在山西省、河南省和江西省招募
7 543名妇女，采用hrHPV DNA检测和E6蛋白检测（Onco E6）等方法进行宫颈癌筛查，任一结果阳性者转诊阴道镜并取活检，于1
年后随访。纳入基线 hrHPV阳性或病理诊断CIN1者。结果：共纳入 794例满足条件妇女，1年后 88例妇女病理级别发生进展。
基线hrHPV DNA中高载量者进展的风险是低载量者的2.9倍（95%CI为1.8～4.8），hrHPV16/18/45、E6蛋白阳性者进展的风险分
别是阴性者的2.4倍（95%CI为1.5～3.9）、2.9倍（95%CI为1.5～5.9），其进展至宫颈上皮内瘤样病变2级及以上（cervical intraepi⁃
thelial neoplasia grade 2 or worse，CIN2+）的绝对风险分别为4.9%（95%CI为3.2～7.4）、9.0%（95%CI为5.5～14.3）、18.8%（95%CI为
10.2～31.9）。hrHPV16/18/45中高载量且E6蛋白（Onco E6）阳性妇女进展的绝对风险高达 32.4%（11/34）。结论：hrHPV DNA中
高载量、hrHPV16/18/45分型以及E6蛋白（Onco E6）可作为妇女 hrHPV阳性和CIN1进展的生物学标志物，特别是 hrHPV中高载
量且E6蛋白（Onco E6）阳性妇女，临床应给予密切随访。
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步扩大和高危型人乳头瘤病毒（high risk human papil⁃
lomavirus，hrHPV）DNA检测的推广应用，越来越多的
hrHPV阳性和宫颈上皮内瘤样病变 1级（cervical in⁃
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